drugset / Trial / NCT03917914
Preventing Adverse Cardiac Events in COPD
Phase 3
Completed
280 enrolled
The George Institute
National Health and Medical Research Council, Australia · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A double-blind, randomised controlled trial in participants with COPD to assess the efficacy of proactive treatment of cardiac risk in people with COPD. We hypothesise that treating known and undiagnosed CVD in COPD participants will improve both cardiac and respiratory outcomes.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
Publications
- Jenkins CR, Martin A, Chang CL, Beasley R, Wrobel JP, McDonald VM, Dobler CC, Yang IA, Farah CS, Cochrane B, Hillis GS, Polak Scowcroft C, Ranasinha CD, De Silva HA, Aggarwal AN, Billot L, Devaux A, Gianacas C, Galgey S, Hancox RJ; PACE investigators. Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Respir Med. 2026 Mar;14(3):203-214. doi: 10.1016/S2213-2600(25)00390-X. Epub 2026 Jan 21.
- Martin A, Hancox RJ, Chang CL, Beasley R, Wrobel J, McDonald V, Dobler CC, Yang IA, Farah CS, Cochrane B, Hillis GS, Scowcroft CP, Aggarwal A, Di Tanna GL, Balicki G, Galgey S, Jenkins C. Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD. BMJ Open. 2021 Aug 27;11(8):e053446. doi: 10.1136/bmjopen-2021-053446.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bisoprolol | Other / unclassified | 1.25 mg | Oral |
| Comparator | Bisoprolol | Other / unclassified | 2.5 mg | Oral |
| Comparator | Bisoprolol | Other / unclassified | 5 mg | Oral |